AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8778430
Drug: Free oral
RxNorm normalized name: CariFree Oral Paste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free oral fluids
Trial: 2055080
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration via instillation into the endotracheal tube (2 mg/kg, diluted to 10 mL)
Trial: 2055080
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration via bronchoscope deep endotracheally
Trial: 2055080
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration via bronchoscope into the right main bronchus
Trial: 2055080
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration via bronchoscope into the right lower lobe bronchus
Trial: 6667814
Drug: Intravenous dl-carnitine
RxNorm normalized name: DL-CARNITINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dl-carnitine infusion
Trial: 30076787
Drug: Dulaglutide once
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide once weekly
Trial: 25656058
Drug: Liraglutide once
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide once daily
Trial: 20628336
Drug: Platelet gels
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet gels
Trial: 9809945
Drug: L-arginine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (2 x 8 g/day)
Trial: 9809945
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hemodynamically active treatment)
Trial: 7484753
Drug: rTPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTPA therapy
Trial: 2702795
Drug: Metoprolol (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.07 mg/kg) followed by isoproterenol (50 micrograms/min)
Trial: 2702795
Drug: Metoprolol (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.07 mg/kg)
Trial: 368231
Drug: Sucrose electrolyte
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose electrolyte solution
Trial: 31120173
Drug: Topical anti-wrinkle
RxNorm normalized name: Anti Bac Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anti-wrinkle cream (AM cream) only
Trial: 31120173
Drug: Topical anti-wrinkle
RxNorm normalized name: Anti Bac Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anti-wrinkle cream (AM cream) and topical evening DNA repair serum (PM serum)
Trial: 28533053
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine trial participants (n = 51)
Trial: 26278124
Drug: Corticosteroid OMP
RxNorm normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid OMP (dexamethasone 2.5 mg, 5 tablets taken on 2 consecutive days weekly)
Trial: 22825550
Drug: BCAA granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA granules (nocturnal administration)
Trial: 22825550
Drug: BCAA granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA granules (daytime administration)
Trial: 3607576
Drug: Alizapride (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (14 mg/kg)
Trial: 3607576
Drug: Prochlorperazine (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (0.56 mg/kg)
Trial: 28303751
Drug: Bevacizumab-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-containing treatment
Trial: 25881090
Drug: Probiotics administered
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administered orally for 6 days preoperatively and 10 days postoperatively.
Trial: 24078623
Drug: Postrelease planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postrelease planning for improving HIV medication adherence
Trial: 24078623
Drug: Postrelease planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postrelease planning for reducing sexual and injection drug-related transmission risk
Trial: 16484823
Drug: PenV 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PenV 1.5 million IU thrice daily for 20 days
Trial: 16484823
Drug: PenV 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PenV 1.5 million IU thrice daily for 14 days
Trial: 11345746
Drug: Milrinone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (loading dose of 50 micrograms.kg‐1 and continuous infusion of 0.5 microgram.kg‐1.min‐1)
Trial: 11345746
Drug: Control (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (dopamine and nitroglycerine administered)
Trial: 8239591
Drug: Doxycycline plus
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline plus rifampin (200 mg of doxycycline plus 600 mg of rifampin once daily for 6 weeks)
Trial: 8239591
Drug: Ofloxacin plus
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin plus rifampin (400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks)
Trial: 25039282
Drug: VR-CP (bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR-CP (bortezomib 1.6 mg/m², rituximab 375 mg/m², cyclophosphamide 1000 mg/m², prednisone 100 mg)
Trial: 25039282
Drug: VR-CAP (bortezomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR-CAP (bortezomib, rituximab, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone)
Trial: 22200806
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg over 4 h in 500 ml of normal saline) administered monthly for 6 months
Trial: 19879973
Drug: Sodium chenodeoxycholate
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chenodeoxycholate (CDC) 500 mg or 1000 mg, given for 4 days
Trial: 19879973
Drug: Colesevelam (1.875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (1.875 g, twice daily)
Trial: 18052925
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil meal (31 g of mixed fat and 9 g of fish oil)
Trial: 18052925
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil meal (40 g of mixed fat)
Trial: 12587957
Drug: Colon-targeted tablet-20
RxNorm normalized name: COLON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon-targeted tablet-20
Trial: 12587957
Drug: Colon-targeted tablet-30
RxNorm normalized name: COLON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon-targeted tablet-30
Trial: 12587957
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release capsules
Trial: 9598887
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 1 mg/kg/day for 6 months
Trial: 29129174
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration oxygen therapy (delivered via Hudson mask at 8 L/min, without regard to Spo2)
Trial: 29129174
Drug: Titrated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oxygen therapy (oxygen delivered via nasal prongs to achieve peripheral oxygen saturation [Spo2] of 88‐92%)
Trial: 17013922
Drug: Piribedil (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (150-300 mg/day)
Trial: 15233676
Drug: Tegaserod (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (both doses)
Trial: 9296407
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg I.V. dolasetron
Trial: 9296407
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg I.V. dolasetron
Trial: 9296407
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg I.V. dolasetron
Trial: 9296407
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg I.V. dolasetron
Trial: 30361335
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control for glycemic control)
Trial: 30361335
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control for BP control)
Trial: 27538108
Drug: Skin needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin needling plus silicone gel (Group A)
Trial: 27538108
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel plus skin needling (Group B)
Trial: 27538108
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel (Control for Group B)
Trial: 19880501
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg orally, days 1 to 28 plus adriamycin and dexamethasone
Trial: 19880501
Drug: Thalidomide 50
RxNorm normalized name: thalidomide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 50 mg daily (maintenance)
Trial: 17675321
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebulised rhDNase
Trial: 17675321
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation and bronchodilator treatments
Trial: 17142512
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza vaccine-trivalent
Trial: 12576620
Drug: Erythromycin treatment
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin treatment for chancroid
Trial: 12576620
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose regimens for H ducreyi infection
Trial: 8678100
Drug: Cefepime high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime high-dose
Trial: 4008115
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ketotifen + 300 mg theophylline
Trial: 4008115
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ketotifen + 600 mg theophylline
Trial: 4008115
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ketotifen
Trial: 4008115
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg theophylline
Trial: 22946072
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy‐based guided self‐management intervention adapted for Maori
Trial: 12005116
Drug: Sodium lauryl
RxNorm normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lauryl sulphate (SLS) 0.25% and 0.5% patch test
Trial: 12005116
Drug: Sodium lauryl
RxNorm normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lauryl sulphate (SLS) patch test
Trial: 7822659
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone tapered over 8 days with intramuscular placebo
Trial: 7822659
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone sodium acetate and oral placebo
Trial: 2120986
Drug: ioversol-320 (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioversol-320 (32 g iodine)
Trial: 2120986
Drug: iohexol-300 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol-300 (45 g iodine)
Trial: 30649973
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (P + C)
Trial: 29070849
Drug: Rituximab-containing therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab-containing therapies
Trial: 23574571
Drug: Anti-wrinkle cream
RxNorm normalized name: CAFFEINE 1300 mg in 130 g / COLLAGEN, SOLUBLE, FISH SKIN 6500 mg in 130 g / HYALURONIC ACID 6500 mg in 130 g / RETINOL 1170 mg in 130 g / SHEA BUTTER 5200 mg in 130 g / JOJOBA OIL 1300 mg in 130 g TOPICAL CREAM [AOAO Retiol Anti-Wrinkle Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-wrinkle cream containing retinol, hyaluronic acid, and dihydroxymethylchromone
Trial: 21059877
Drug: RME followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RME followed by TPA therapy plus extraction of deciduous canines (RME/TPA/EC group, 40 subjects)
Trial: 21059877
Drug: TPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA therapy plus extraction of deciduous canines (TPA/EC group, 25 subjects)
Trial: 21059877
Drug: No orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No orthodontic treatment (Control group, CG, 30 subjects)
Trial: 8932837
Drug: Cyclophosphamide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by autologous bone marrow transplantation (ABMT)
Trial: 8932837
Drug: Cyclophosphamide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by ABMT
Trial: 28505956
Drug: Non‐invasive Spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐invasive Spinal Decompression Therapy (NSDT)
Trial: 28505956
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of electrotherapy, deep friction massage, and stabilization exercise (Control Group)
Trial: 25384624
Drug: Split virion
RxNorm normalized name: Influenza A virus A/Kansas/14/2017 (H3N2)-like virus strain split virion hemagglutinin Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split virion vaccine
Trial: 25384624
Drug: Whole virion
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virion vaccine
Trial: 25384624
Drug: Split virion
RxNorm normalized name: Influenza A virus A/Kansas/14/2017 (H3N2)-like virus strain split virion hemagglutinin Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split virion vaccine with anti-TNF-α therapy
Trial: 23068310
Drug: sucking-oral sucrose-tucking
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucking-oral sucrose-tucking
Trial: 23068310
Drug: sucking-oral sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucking-oral sucrose
Trial: 23068310
Drug: oral sucrose-tucking
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral sucrose-tucking
Trial: 19366972
Drug: Intravenous glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glulisine insulin
Trial: 19366972
Drug: Subcutaneous glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous glargine and glulisine
Trial: 19366972
Drug: Subcutaneous NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous NPH and regular insulin
Trial: 15305945
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of inhaled budesonide
Trial: 15305945
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with inhaled budesonide
Trial: 9386112
Drug: Intravenous vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vasopressin (0.1 U/min)
Trial: 7910053
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with thymosin alpha 1, interferon-alpha, and zidovudine
Trial: 7910053
Drug: Zidovudine alone
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine alone or associated with single agents
Trial: 3064642
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (100 mg/day) for 10 days
Trial: 3064642
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 10 days
Trial: 29347848
Drug: Intravaginal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal oxytocin gel
Trial: 19595100
Drug: Screw canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screw canal preparation time
Trial: 12734858
Drug: Gastrografin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (100 ml)
Trial: 10647721
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml intracameral, unpreserved, epinephrine‐free 1% lidocaine
Trial: 9052889
Drug: Intrabrachial acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 mL per minute)
Trial: 9052889
Drug: L-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (1 micromol/100 mL per minute)
Trial: 9052889
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 microg/100 mL per minute)
Trial: 9052889
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (1, 2, and 4 microg/100 mL per minute)
Trial: 8346005
Drug: Trivalent cold‐adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold‐adapted recombinant influenza vaccine
Trial: 25394440
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (50 μg) and normal saline (10 mL)
Trial: 25394440
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (50 μg) and bupivacaine (0.5%; 10 mL)
Trial: 23328343
Drug: Multidisciplinary program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary program consisting of cognitive-behavior therapy and exercise training
Trial: 9469675
Drug: Ziprasidone 20
RxNorm normalized name: ziprasidone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20 mg administered under fasting conditions (treatment A)
Trial: 9469675
Drug: Ziprasidone 20
RxNorm normalized name: ziprasidone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20 mg administered directly after a standard high-fat breakfast (treatment B)
Trial: 9469675
Drug: Ziprasidone 20
RxNorm normalized name: ziprasidone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20 mg administered 2 hours after a standard high-fat breakfast (treatment C)
Trial: 27424688
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 22 mg/kg/day
Trial: 2209678
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2 mg/kg/day
Trial: 20430115
Drug: Usual primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual primary prevention care plus bespoke lifestyle support (treatment)
Trial: 12438948
Drug: Sirolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (5 mg daily after a 15 mg loading dose, concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter)
Trial: 12438948
Drug: Cyclosporine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (6 to 8 mg/kg per day in divided doses, concentration-controlled to keep 12-hr troughs of 200 to 250 ng/mL)
Trial: 7781416
Drug: Surgery combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery combined with chemotherapy and radiotherapy
Trial: 6104451
Drug: KWD 2131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KWD 2131 (0.5 mg to 12 mg)
Trial: 6104451
Drug: Terbutaline (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.05 mg to 1.2 mg)
Trial: 28239805
Drug: Closed-loop target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop target controlled infusion (CLTCI) of cisatracurium